00

Hefei Lifeon Pharmaceutical Co Ltd

003020 · SHE · Healthcare / Biotechnology

14.87CNY-0.25 (-1.65%)

Price History

Full chart

Market Stats

Previous Close15.12
Open15.12
Day Range14.83 – 15.28
52-Week Range14.20 – 26.33
Volume1.78M
Market Cap3.94B
P/E (TTM)23.97
Forward P/E0.00
EPS0.72
Dividend Yield2.70%
Beta-0.16
50-Day Avg17.62
200-Day Avg19.12

About

Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethylphenidate HCL, dioctyl sulfosuccinate sodium salt, and DMSA. It also provides intermediate products, such as sodium paeonolsilate, methy2-(2,3-dichlorobenzylidine)-acetoacetate, 3-mercapto-1-propanol, mercaptosuccinic acid and DMPS monohydrate. In addition, it offers nifedipine controlled, doxazosin mesylate, felodipine, trimetazidine dihydrochloride prolonged release tablets; venlafaxine, methylphenidate, and oxycodone hydrochloride prolonged release tablets; chinese medicines; and proxymetacaine hydrochloride, bendazac lysine, timolol maleate, gatifloxacin, jinzhen, pemirolast potassium, and compound dextran eye drops. Further, it provides paeonol ointment, kecuo yintong gel, compound tujingpi gel, metformin and glipizide tablets, and itraconazole and armillarisin oral solution. The company was incorporated in 2002 and is based in Hefei, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Huanxi Cui
  • Employees1.47K
  • HeadquartersCube Factory, Hefei, China, 230088, China
  • Websitehttps://www.lifeonapi.com

Leadership

  • Mr. Huanxi CuiGM & Director · b. 1979
  • Ms. Yi LiuCFO & Head of Accounting · b. 1988
  • Mr. Tianhe DaiDeputy General Manager · b. 1977
  • Mr. Tiecheng JiDeputy GM & Director · b. 1992
  • Mr. Jun XiaDeputy GM & Secretary of the Board · b. 1983
  • Mr. Yong ZhengDeputy General Manager · b. 1972

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue733.32M877.72M962.17M1.03B1.17B1.42B1.65B1.89B2.27B2.58B1.90B1.52B1.55B
Growth (%)-+19.69%+9.62%+6.86%+13.46%+22.12%+15.83%+14.80%+20.01%+13.46%-26.31%-20.11%+2.33%
Cost of Revenue598.25M709.42M786.35M839.69M908.95M998.93M1.13B1.26B1.37B1.62B932.11M479.46M550.81M
Gross Profit135.07M168.30M175.82M188.48M257.62M425.65M515.76M632.60M904.36M960.28M968.68M1.04B1.00B
Gross Margin18.42%19.18%18.27%18.33%22.08%29.88%31.26%33.40%39.78%37.23%50.96%68.43%64.55%
Operating Expense97.14M118.05M117.48M113.34M167.66M317.38M396.92M475.16M711.90M720.22M713.41M861.29M836.69M
Operating Income37.93M50.26M58.34M75.14M89.96M108.27M118.84M157.44M192.45M240.05M255.27M177.73M166.30M
Operating Margin5.17%5.73%6.06%7.31%7.71%7.60%7.20%8.31%8.47%9.31%13.43%11.70%10.70%
EBITDA57.75M67.74M74.12M94.21M104.77M122.20M136.58M173.41M223.95M266.65M294.53M248.72M274.62M
EBITDA Margin7.88%7.72%7.70%9.16%8.98%8.58%8.28%9.15%9.85%10.34%15.50%16.38%17.67%
Net Income36.69M47.02M53.82M67.46M76.82M91.66M105.14M135.12M172.23M209.25M226.67M160.60M165.19M
Net Income Margin5.00%5.36%5.59%6.56%6.59%6.43%6.37%7.13%7.58%8.11%11.93%10.58%10.63%
R&D6.71M9.10M9.19M11.80M18.39M23.79M39.14M47.54M71.80M76.25M94.89M91.86M110.78M
R&D as % of Total Revenue0.92%1.04%0.96%1.15%1.58%1.67%2.37%2.51%3.16%2.96%4.99%6.05%7.13%
Interest Expense2.39M4.23M4.06M2.54M3.33M2.87M1.47M519.12K1.57M1.25M1.40M2.00M2.34M
Interest Expense % of Total Revenue0.33%0.48%0.42%0.25%0.29%0.20%0.09%0.03%0.07%0.05%0.07%0.13%0.15%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets358.64M446.22M475.64M547.80M612.85M771.01M889.81M1.54B1.67B2.12B2.48B2.59B2.59B
Total Liabilities216.67M269.34M260.11M249.71M251.14M265.31M299.82M362.03M370.53M641.53M610.18M673.38M634.19M
Total Equity141.38M178.50M219.12M298.09M361.71M505.70M590.00M1.17B1.30B1.48B1.69B1.74B1.81B
Cash49.69M40.23M57.25M75.77M76.43M154.46M223.24M766.59M654.25M642.58M502.93M439.69M413.89M
Total Debt62.00M94.00M72.00M50.00M65.00M35.00M24.04M181.15M24.58M13.41M33.86M64.22M-
Net Debt12.31M53.77M14.75M-25.77M-11.43M-119.46M-199.20M-585.44M-629.67M-629.17M-393.83M-375.48M-

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.96M35.54M92.05M58.99M11.32M64.45M149.30M172.49M158.70M200.64M203.67M197.53M212.89M
Investing Cash Flow-36.36M-44.42M-34.01M-26.22M-7.41M-6.19M-43.80M-56.19M-191.88M-201.80M-440.60M-182.23M-
Financing Cash Flow40.12M18.74M-36.86M-20.17M5.00M-5.28M-25.79M408.44M-58.50M-47.95M36.63M-78.33M-
Capital Expenditure30.12M44.43M34.01M12.74M11.46M29.16M43.90M56.20M186.95M246.43M197.54M154.49M118.46M
Free Cash Flow-38.08M-8.89M58.04M46.25M-131.90K35.30M105.40M116.29M-28.24M-45.79M6.14M43.05M94.43M
Dividends Paid9.54M14.81M17.60M22.34M16.34M22.40M20.84M27.79M46.32M64.85M61.28M80.93M166.16M
FCF to OCF478.56%-25.01%63.05%78.40%-1.16%54.76%70.59%67.42%-17.80%-22.82%3.01%21.79%44.36%
Dividend Paid to FCF-25.05%-166.66%30.32%48.29%-12386.66%63.47%19.78%23.90%-164.00%-141.63%998.52%188.02%175.97%

Earnings

Report DateDec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Apr 29, 2022Aug 27, 2022Oct 31, 2022Dec 31, 2022Apr 17, 2023Aug 28, 2023Oct 30, 2023Dec 31, 2023Apr 29, 2024Jun 30, 2024Oct 29, 2024Dec 31, 2024Apr 21, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------
EPS Actual0.160.180.190.190.210.390.420.590.170.550.410.260.240.190.210.220.180.200.230.130.190.150.23
Surprise-----------------------
Timing-----Pre-marketAfter-hoursPre-market-Pre-marketPre-marketAfter-hours-Pre-market-Pre-market-Pre-market-----

Key Statistics & Ratios

Market Cap3.94B
Enterprise Value3.59B
Trailing P/E23.97
Forward P/E0.00
Price / Sales2.62
Price / Book2.20
EPS0.72
Book Value8.06
Revenue (TTM)1.51B
Gross Profit (TTM)980.27M
EBITDA235.19M
Profit Margin10.84%
Operating Margin14.35%
Return on Equity8.05%
Return on Assets3.59%
Shares Outstanding228.22M
Shares Float98.13M
Beta-0.16
Dividend Yield2.70%
Dividend Rate0.47
Payout Ratio65.27%

Dividends

20261×
0.30May 29, 2026
20253×
0.17Nov 28, 20250.25May 22, 20250.17Jan 21, 2025
20241×
0.42May 28, 2024
20231×
0.35May 24, 2023
20221×
0.37May 23, 2022
20211×
0.21May 21, 2021

Stock Splits

  • May 29, 20261.2:1
  • May 28, 20241.2:1
  • May 24, 20231.3:1
  • May 23, 20221.3:1